Hematologist
CION Cancer Clinics
FLT3, NPM1 and IDH in AML: why mutations matter | CION Cancer Clinics
FLT3 positive means the leukaemia cells carry a change in the FLT3 gene that keeps them growing. It is found in about one in three adults with AML and is not inherited. It matters because it adds a targeted medicine to treatment and can bring an early transplant discussion. This page explains FLT3, NPM1 and IDH results, how they are tested, and what they cannot tell you. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does "FLT3 positive" mean on an AML report?
- What does each of these mutations mean?
- How and when are these mutations tested?
- How does a mutation change the treatment?
- Which words on a mutation report should you know?
- What do families often get wrong about AML mutations?
- What can a mutation result not tell you?
- Common questions about FLT3, NPM1 and IDH
The short answer
What does "FLT3 positive" mean on an AML report?
FLT3 positive means the leukaemia cells carry a change in a gene called FLT3, which acts like a switch stuck in the "grow" position. It is found in about one in three adults with AML, and it matters because it changes the medicines your team adds to chemotherapy.
Where the mutation is, and where it is not
The change is in the leukaemia cells only. It happened during your life, inside the marrow. It is not in the rest of your body, it was not passed on from your parents, and your children do not inherit it.
Why FLT3 is tested alongside NPM1 and IDH
AML is now understood through the gene changes that drive it. FLT3, NPM1, IDH1 and IDH2 are among the most important because each one affects either how the leukaemia is likely to behave, or which targeted medicine can be used against it. They are usually checked together at diagnosis on the same marrow or blood sample.
What the result is used for
Your team uses these results to choose treatment, to place you in a risk group, and sometimes to track tiny amounts of leukaemia left after treatment.
If the report does not mention FLT3, NPM1 or IDH, ask whether the tests were sent. They are part of a standard AML work-up.The four names
What does each of these mutations mean?
Each gene change says something different. Many people have more than one, and they are read together.
FLT3-ITD
A stretch of the gene is copied twice. The leukaemia tends to grow fast and has a higher chance of coming back after chemotherapy alone.
Often leads to
- A FLT3 inhibitor added to chemotherapy
- An early talk about transplant
FLT3-TKD
A small single-letter change in another part of the gene. Its effect on outlook is less clear than ITD, but some FLT3 medicines still work against it.
NPM1
One of the most common changes in adult AML. On its own, without FLT3-ITD, it often means the leukaemia responds well to standard chemotherapy.
NPM1 can also be tracked in the blood to watch for early signs of relapse.IDH1 and IDH2
Changes that cause the cell to build up a substance that blocks it from maturing. Targeted tablets exist for each, used in some people who cannot take intensive chemotherapy or whose AML returns.
Not sure whether this applies to you?
Ask an oncologistThe test
How and when are these mutations tested?
Sample at diagnosis
The same marrow sample used to confirm AML is sent for gene testing. Sometimes blood is used if it has plenty of blasts. You do not need a separate procedure.
Rapid FLT3 result
Labs try to report FLT3 within a few days, because a FLT3 medicine is added early in induction. Ask your team when to expect it.
Wider gene panel
A larger panel checks NPM1, IDH1, IDH2, TP53 and other genes. This can take longer, and the plan is refined when it arrives.
Repeat tests later
Tests are often repeated at relapse, because the leukaemia can gain or lose a mutation. A new FLT3 or IDH change can open a different option.
What changes
How does a mutation change the treatment?
A mutation result mainly changes which targeted medicine is added, and whether a transplant is discussed early. It does not replace the core treatment, which your haematologist builds around your fitness and your full set of results.
If FLT3 is found
For people fit for intensive treatment, a FLT3 inhibitor such as midostaurin or quizartinib is often added to induction chemotherapy. If the leukaemia returns with a FLT3 change, gilteritinib is one medicine that may be considered. Your team chooses and sets the dose.
If IDH1 or IDH2 is found
Ivosidenib targets IDH1 and enasidenib targets IDH2. They are more often used for AML that has come back, or with gentler treatment in people who cannot take intensive chemotherapy.
Who these medicines do not suit
They only help when the matching mutation is present. Some cause heart rhythm changes or a reaction where blasts suddenly mature, so they are not right for everyone. Access and cost can also be limiting, and your team should discuss that openly.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
On your report
Which words on a mutation report should you know?
- Detected / not detected
- Whether the change was found in the sample. "Not detected" means not found by that test, at that time.
- ITD and TKD
- The two kinds of FLT3 change: a copied stretch of the gene, or a single-letter change.
- Allelic ratio or VAF
- A measure of how much of the mutated gene is present compared with the normal copy. Your team reads it with the rest of the results.
- MRD
- Measurable residual disease. Very small amounts of leukaemia found after treatment by sensitive tests, often using NPM1.
- Wild type
- The normal version of the gene, with no mutation found.
Commonly believed
What do families often get wrong about AML mutations?
"A mutation means our children will get AML."
FLT3, NPM1 and IDH changes in AML are found in the leukaemia cells, not in the eggs or sperm. They are not passed down. Rare inherited risks exist, but they are tested differently and your team will say if that is relevant.
"FLT3 positive means nothing can be done."
It used to mean a harder road. Today there are medicines designed against FLT3, and the result helps the team plan more precisely, including when to consider a transplant.
"The tablet can replace chemotherapy."
For most fit adults, targeted medicines are added to chemotherapy, not used instead of it. Stopping or skipping either on your own can let the leukaemia grow back.
"No mutation found means a good outlook."
Not always. Chromosome results, other genes, age and response to treatment also count. Read the whole report, not one line.
Being straight with you
What can a mutation result not tell you?
A single mutation cannot tell you how long anyone will live or whether treatment will work for you. It shifts the odds for a large group of people, and your own picture depends on everything else as well.
Why results are read together
NPM1 with FLT3-ITD means something different from NPM1 alone. A TP53 change can outweigh a favourable finding. That is why haematologists use risk systems that combine all the results rather than reacting to one gene.
What to ask your team
Ask which mutations were tested, which were found, whether any targeted medicine applies, and whether a transplant is being considered.
CION's haematology team reviews the full report, presents the case at a tumour board and coordinates specialised tests or transplant with qualified centres where needed.Questions we are asked
Common questions about FLT3, NPM1 and IDH
Is FLT3-positive AML worse?
FLT3-ITD has historically carried a higher chance of the leukaemia coming back after chemotherapy alone. Adding a FLT3 medicine and, for some people, a transplant is meant to address that. How it affects your own outlook depends on your other results, so ask your haematologist to explain it for you specifically.
Is NPM1 a good mutation to have?
No mutation is good, but NPM1 without FLT3-ITD is often linked with a better response to standard chemotherapy. When FLT3-ITD or certain chromosome changes are present too, the picture changes. It is the combination, not NPM1 alone, that places you in a risk group.
How long does FLT3 testing take?
Many labs report FLT3 within a few days because it guides early treatment. A wider gene panel can take longer. If you have not heard after the first week of treatment, it is fair to ask where the result is and whether the sample reached the lab.
Are FLT3 and IDH medicines available in India?
Several are approved and used in India, though availability, cost and scheme coverage vary and change over time. Your haematologist can tell you what is currently accessible for your situation. Never buy or start one on your own, as monitoring for side effects is essential.
Can the mutation disappear after treatment?
Yes. If treatment clears the leukaemia cells, the mutation is no longer detected, because it only lived in those cells. Sensitive tests may be repeated to look for tiny amounts left behind. A mutation can also reappear or change if the leukaemia comes back.
Do family members need a blood test for this?
Not for FLT3, NPM1 or IDH, because these are not inherited. Family members may be tested later for a different reason, to see whether a brother or sister could be a stem cell donor if a transplant is planned. Your team will tell you if and when.
Does a FLT3 medicine have side effects?
Yes. They can include sickness, loose motions, liver test changes and heart rhythm changes, and blood counts are watched closely. The pattern differs between medicines. Report any new symptom to your team rather than stopping the medicine yourself.
What if my report says FLT3 not tested?
Ask your haematologist why, and whether stored sample can still be sent. In most adults with AML fit for treatment, FLT3 testing is part of the standard work-up. It can also be requested for a second opinion if the original sample is available.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Tests for Acute Myeloid Leukemia (AML)
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia (AML)
- Cancer Research UK — Acute myeloid leukaemia (AML)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Have a mutation report you cannot read?
Share it with us. CION's haematology team will explain what the results mean for the plan. One helpline serves every CION centre.